Psychedelics are serotonin 2A receptor agonists that can lead to profound changes in
perception, cognition and mood. In this review, we focus on the basic neurobiology …

Psychedelic drugs including psilocybin, N, N ʹ-dimethyltryptamine (DMT) and lysergic acid
diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various …

Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric
diseases, and the ability to promote cortical neuron growth has been hypothesized to …

Drugs that target the human serotonin 2A receptor (5-HT2AR) are used to treat
neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use …

5-HT receptors expressed throughout the human body are targets for established
therapeutics and various drugs in development. Their diversity of structure and function …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter
perception and mood and affect numerous cognitive processes. They are generally …

Ligands can induce G protein-coupled receptors (GPCRs) to adopt a myriad of
conformations, many of which play critical roles in determining the activation of specific …

In addition to producing profound subjective effects following acute administration,
psychedelic compounds can induce beneficial behavioral changes relevant to the treatment …